Posting: # 320
Please let me know the Quantity of retention sample to be retained at the BA/BE center after completion of the trial.
@ prashant modi
Posting: # 326
» Please let me know the Quantity of retention sample to be retained at the BA/BE center after completion of the trial.
Are you talking about (I) the drug products or (II) the bioanalysis samples?
I: Depending on the country’s regulation. Unused drug may either be destroyed, send back to the sponsor, or some samples may be retained. In any case records about the procedures followed have to kept.
VI. RESPONSIBiLITIES IN VARIOUS STUDY SETTINGS
A.Studies Conducted at CROs, Universities, Hospitals, or Physicians’ Offices
The responsibilities of the testing facility are as follows:
(2) The sponsor shall maintain complete and accurate records to establish that the clinical trial is conducted in accordance with good clinical practices and these Regulations.
(3) The sponsor shall maintain complete and accurate records in respect of the use of a drug in a clinical trial, including:
e. records respecting the shipment, receipt, disposition, return and destruction of the drug;
(4) The sponsor shall maintain all records referred to in this Division for a period of 25 years.
Article 11 (Quality control)
2. […] For investigational medicinal products, the sponsor shall ensure that the contract laboratory complies with the content of the request referred to in Article 9(2) of Directive 2001/20/EC, as accepted by the competent authority. When the products are imported from third countries, analytical control shall not be mandatory.
4. […] Samples of each batch of finished medicinal product shall be retained for at least one year after the expiry date.
8. RETENTION OF BA/BE SAMPLES
All samples of test and reference drug products used in bioavailability / bioequivalence study should be retained by the organization carrying out the bioavailability / bioequivalence study for a period of three years after the conduct of the study or one year after the expiry of the drug, whichever is earlier. The study sponsor and/or drug manufacturer should provide to the testing facility batches of the test and reference drug products in such a manner that the reserve samples can be selected randomly. This is to ensure that the samples are in fact representative of the batches provided by the study sponsor and/or drug manufacturer and that they are retained in their original containers. Each reserve sample should consist of a quantity sufficient to carry out twice all the in-vitro and in-vivo tests required during bioavailability / bioequivalence study.
The reserve sample should be stored under conditions consistent with product labelling and in an area segregated from the area where testing is conducted and with access limited to authorized personnel.
II: IMHO no specific guidelines exist, but a commonly applied rule is:
All the best,
The quality of responses received is directly proportional to the quality of the question asked. ☼